Rosacea Clinical Trial
Official title:
A Vehicle-Controlled, Double-Blind, Randomized Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Rosacea
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea. At Screening and Baseline all subjects must have Type 1 erythematotelangiectatic rosacea (ETR). The total duration of the study will be approximately 12 weeks. Participants will report for a Screening visit and if all inclusion criteria are met will undergo a washout period, between 2 days and 4 weeks, depending on current treatment. Subjects will then report for the Baseline visit. Subjects will come in for visits at Day 7 (Week 1), Day 28 (Week 4), and Day 56 (Week 8). A final visit will be conducted at Day 84 (Week 12). Efficacy will be assessed using Clinician Erythema Assessment (CEA), Investigator Global Assessment (IGA), Skindex16, and Patient Self-Assessment (PSA). Blood and urine samples will be collected for standard safety laboratory tests. Participant's safety will be monitored throughout the study. Investigators plan to enroll approximately 130 subjects. Randomization will be 1:1 so that equal numbers of subjects will be treated in each arm of the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05597462 -
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
|
Phase 1 | |
| Completed |
NCT02601963 -
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
|
Phase 2 | |
| Completed |
NCT02249065 -
Mirvaso in Use Study
|
Phase 4 | |
| Completed |
NCT02292797 -
Assessment of the Rosacea Prevalence in the General Population
|
N/A | |
| Completed |
NCT01659853 -
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
|
Phase 3 | |
| Completed |
NCT01426269 -
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
|
Phase 4 | |
| Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
| Terminated |
NCT04336163 -
Skin Imaging to Inform Laser Treatments
|
N/A | |
| Recruiting |
NCT04108897 -
Analysis of the Microbiome in Rosacea
|
Early Phase 1 | |
| Completed |
NCT03872050 -
Deep Phenotyping of Rosacea and Migraine
|
||
| Active, not recruiting |
NCT06033352 -
Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea
|
Phase 2 | |
| Completed |
NCT03263273 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea
|
Phase 2 | |
| Completed |
NCT04508205 -
CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes
|
Phase 1 | |
| Completed |
NCT04508660 -
CGB-400 for the Reduction of Facial Redness
|
Phase 1 | |
| Completed |
NCT05094700 -
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
|
N/A | |
| Active, not recruiting |
NCT03211585 -
EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA
|
N/A | |
| Completed |
NCT02637232 -
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
|
||
| Completed |
NCT02576847 -
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
|
Phase 3 | |
| Completed |
NCT02576860 -
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
|
Phase 3 | |
| Completed |
NCT02583009 -
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea
|
Phase 2 |